Consistently, in prostate cancer, 15-d-PGJ-2 inhibits the growth and induces partial differentiation of cancer cells, whereas reducing in vitro PGD2 levels by using specific antibodies or its knockdown from the culture medium eliminates tumor cell growth inhibitory effect and restores tumor resistance. Here, PTGDS is linked to prostate carcinoma.